Get the Stockscreener App
15.13
0.20%
0.03
Roivant Sciences Ltd stock is traded at $15.13, with a volume of 6.26M.
It is up +0.20% in the last 24 hours and up +26.82% over the past month.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$15.10
Open:
$15.05
24h Volume:
6.26M
Relative Volume:
0.94
Market Cap:
$10.33B
Revenue:
$125.68M
Net Income/Loss:
$4.81B
P/E Ratio:
2.6779
EPS:
5.65
Net Cash Flow:
$-781.21M
1W Performance:
+2.65%
1M Performance:
+26.82%
6M Performance:
+49.95%
1Y Performance:
+31.11%
1-Day Range:
$14.93
$15.27
1-Week Range:
$14.50
$15.28
52-Week Range:
$8.73
$16.05
Roivant Sciences Ltd Stock (ROIV) Company Profile
Name
Roivant Sciences Ltd
Sector
Industry
Phone
441-295-5950
Address
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
15.13 | 10.31B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-02-25 | Initiated | Citigroup | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Jan-05-24 | Initiated | Piper Sandler | Overweight |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-17-23 | Initiated | Guggenheim | Buy |
| Jun-08-23 | Initiated | BofA Securities | Neutral |
| Oct-27-22 | Initiated | JP Morgan | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-29-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-15-21 | Initiated | Goldman | Buy |
| Nov-08-21 | Initiated | H.C. Wainwright | Buy |
| Oct-28-21 | Initiated | Citigroup | Buy |
| Oct-26-21 | Initiated | Cowen | Outperform |
| Oct-26-21 | Initiated | Jefferies | Buy |
| Oct-26-21 | Initiated | Truist | Buy |
View All
Roivant Sciences Ltd Stock (ROIV) Latest News
Can Roivant Sciences Ltd. (87S) stock double in coming yearsQuarterly Profit Summary & AI Enhanced Trading Signals - newser.com
Will Roivant Sciences Ltd. continue its uptrendEarnings Recap Report & Fast Moving Stock Watchlists - newser.com
Roivant Sciences stock poised for growth, Goldman Sachs reiterates Buy By Investing.com - Investing.com South Africa
Roivant Sciences stock poised for growth, Goldman Sachs reiterates Buy - Investing.com India
Roivant Sciences Ltd.’s volatility index tracking explainedGap Up & Growth Focused Stock Reports - newser.com
Is Roivant Sciences Ltd. (87S) stock undervalued historicallyMarket Activity Summary & AI Driven Stock Price Forecasts - newser.com
Why retail investors pile into Roivant Sciences Ltd. stockBond Market & Real-Time Stock Price Movement Reports - newser.com
Why Roivant Sciences Ltd. (87S) stock attracts wealthy investorsOil Prices & Accurate Technical Buy Alerts - newser.com
What sentiment indicators say about Roivant Sciences Ltd. stockProfit Target & Risk Controlled Stock Alerts - newser.com
Long term hold vs stop loss in Roivant Sciences Ltd.Trade Analysis Report & Long-Term Safe Investment Plans - newser.com
LVW Advisors LLC Makes New $199,000 Investment in Roivant Sciences Ltd. $ROIV - MarketBeat
Can Roivant Sciences Ltd. stock deliver consistent earnings growth2025 Price Action Summary & Expert Curated Trade Ideas - newser.com
What analysts say about Roivant Sciences Ltd stockDividend Stability Analysis & Fast Growing Investment Ideas - earlytimes.in
How Investors May Respond To Roivant Sciences (ROIV) Positive Phase 3 Results for Brepocitinib in Dermatomyositis - simplywall.st
Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Is Roivant Sciences Ltd a good long term investmentVolatility Index Analysis & These Stocks Are Just Getting Started - Early Times
Transcript : Roivant Sciences Ltd. Presents at Bernstein 2nd Annual Global Healthcare Conference, Sep-23-2025 01 - MarketScreener
Transcript : Roivant Sciences Ltd. Presents at Bank of America Global Healthcare Conference 2025, Sep-24-2025 09 - MarketScreener
Roivant Sciences president Venker sells $25.5m in shares By Investing.com - ng.investing.com
Roivant Sciences at Bank of America Global Healthcare: Strategic Insights By Investing.com - Investing.com Australia
analysts-double-sales-forecasts-for-roivant-s-brepocitinib-after-trial-success-93143405 - S&P Global
Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 611,000 Shares - MarketBeat
Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 416,182 Shares - MarketBeat
Roivant Sciences president Venker sells $25.5m in shares - Investing.com
Are You Looking for a Top Momentum Pick? Why Roivant Sciences Ltd. (ROIV) is a Great Choice - Yahoo Finance
Roivant Sciences (NASDAQ:ROIV) Given New $22.00 Price Target at Leerink Partners - MarketBeat
Inspire Investing LLC Invests $303,000 in Roivant Sciences Ltd. $ROIV - MarketBeat
The Goldman Sachs Group Boosts Roivant Sciences (NASDAQ:ROIV) Price Target to $24.00 - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Price Target Raised to $20.00 at HC Wainwright - MarketBeat
Bank of America Forecasts Strong Price Appreciation for Roivant Sciences (NASDAQ:ROIV) Stock - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Guggenheim Boosts Roivant Sciences (NASDAQ:ROIV) Price Target to $21.00 - MarketBeat
Ramaswamy-backed Strive to buy Semler in $1.3 billion deal all stock deal, boosting Bitcoin holdings - Reuters
What is HC Wainwright's Forecast for ROIV Q1 Earnings? - MarketBeat
Leerink Partnrs Has Bullish Estimate for ROIV Q2 Earnings - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Hits New 1-Year HighWhat's Next? - MarketBeat
Roivant Sciences Hits Day High with Strong 7.76% Intraday Surge - Markets Mojo
Roivant Sciences (NASDAQ:ROIV) CEO Matthew Gline Purchases 3,315 Shares - MarketBeat
Roivant Sciences (ROIV): Assessing Valuation After Positive Phase 3 Brepocitinib Results in Dermatomyositis Trial - simplywall.st
History Review: Will Roivant Sciences Ltd benefit from rate cutsOptions Play & Weekly Watchlist for Hot Stocks - خودرو بانک
Ramaswamy Sells $23 Million of Roivant Sciences Stock -- Barron's - 富途牛牛
Peak Financial Advisors LLC Acquires Shares of 41,880 Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences Ltd Stock (ROIV) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):